Is Xeris Biopharma Holdings, Inc. (XERS) Overvalued?
We dive into why Xeris Biopharma Holdings, Inc. (XERS) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Stock Evaluator: Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. XERS
$8.78
-0.07
-0.79%
August 19, 2026 4:00:00 PM
EST
Volume: 2,248,563
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Commentary & Analysis
Why Xeris Biopharma Holdings, Inc.’s (XERS) Stock Is Up 5.64%
As of Friday, August 07, Xeris Biopharma Holdings, Inc.’s XERS share price has surged by 5.64%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Xeris Biopharma Holdings, Inc.’s (XERS) Stock Is Down 10.72%
As of Thursday, August 06, Xeris Biopharma Holdings, Inc.’s XERS share price has dipped by 10.72%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Xeris Biopharma Holdings, Inc.’s (XERS) Stock Is Down 10.11%
As of Thursday, August 06, Xeris Biopharma Holdings, Inc.’s XERS share price has dipped by 10.11%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About Xeris Biopharma Holdings, Inc.'s Q3 Earnings
Xeris Biopharma Holdings, Inc.'s fiscal Q3 earnings report was released on Thursday, August 06. Let's dive in to see if (XERS) missed or beat analyst's expectations.Michael Rose
Financial Summary
| Share Statistics | XERS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,568.0 | $618.0 | 50% |
|
| Shares Out (Mil) | 172.8 | 44.8 | 73% |
|
| Institutional Ownership | 94.6% | 85.3% | 65% |
|
| Float (Mil) | 176.0 | 47.4 | 72% |
|
| Beta | 0.85 | 0.70 | 51% |
|
| Avg Daily Volume (000s) | 1,784 | 390 | 80% |
|
| Price Change (52-week) |
16.9% | 68.6% | 59% |
|
| Growth | XERS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 70.3% | 6.7% | 98% |
|
| Net Income (5yr) | 14.9% | (1.6%) | 63% |
|
| EPS (5yr) | 14.9% | 14.9% | 55 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (9.9%) | (14.9%) | 58% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.020) | ($0.003) | $0.390 | |
| Month Ago EPS | $0.040 | $0.143 | $0.393 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.043 | $0.143 | $0.395 | |
| Year/Year Chg | (88.9%) | (200.0%) | 21,133% | |
| Financials | XERS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $335 | $291 | 37% |
|
| Net Income (TTM) (Mil) | ($17) | ($11) | 25% |
|
| EPS (TTM) | ($0.102) | ($0.700) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | $57 | ($6) | 47% |
|
| Net Cash Flow (TTM) (Mil) | $62 | $5 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $219 | $6 | 51% |
|
| Enterprise Value (Q1) (Mil) | $1,614 | $450 | 46% |
|
| Valuation | XERS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | XERS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.6% | 67.0% | 92% |
|
| Net Margin | (5.1%) | (2.3%) | 25% |
|
| ROA | (4.6%) | (22.4%) | 30% |
|
| ROE | 118.2% | (20.2%) | 97% |
|
| Liabilities to Assets | 102.4% | 32.2% | 94% |
|
| F-Score | 6 | 3 | 67% |
|
Xeris Biopharma Holdings, Inc. did not pass any screens on 8/20/2026.
